Roche's Genentech Presents Updated Clinical Results for Enicepatide and Petrelintide at ADA 2026

Genentech, a unit of Roche (RHHBY), released updated clinical data for its investigational drug candidates enicepatide and petrelintide on June 1, 2026, during the American Diabetes Association’s annual meeting. The presentation detailed new safety and efficacy analyses from ongoing trials of the two metabolic disease therapies. The compounds are part of Roche’s push into the lucrative diabetes and obesity market, competing against established GLP-1 agonists. While specific efficacy figures were not immediately detailed, the company highlighted improvements in key metabolic markers. Roche shares showed little reaction in midday trading.